Group One Trading’s Provention Bio, Inc. Common Stock PRVB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-78,600
| Closed | -$1.89M | – | 8487 |
|
|
2023
Q1 | $1.89M | Sell |
78,600
-66,000
| -46% | -$828K | 0.01% | 1583 |
|
|
2022
Q4 | $1.53M | Buy |
144,600
+94,200
| +187% | +$760K | ﹤0.01% | 2060 |
|
|
2022
Q3 | $227K | Buy |
50,400
+800
| +2% | +$3.65K | ﹤0.01% | 4014 |
|
|
2022
Q2 | $198K | Sell |
49,600
-9,600
| -16% | -$45.5K | ﹤0.01% | 4321 |
|
|
2022
Q1 | $433K | Sell |
59,200
-11,700
| -17% | -$70K | ﹤0.01% | 3977 |
|
|
2021
Q4 | $398K | Buy |
70,900
+26,500
| +60% | +$168K | ﹤0.01% | 4388 |
|
|
2021
Q3 | $284K | Sell |
44,400
-84,500
| -66% | -$543K | ﹤0.01% | 4808 |
|
|
2021
Q2 | $1.09M | Buy |
128,900
+89,800
| +230% | +$725K | ﹤0.01% | 3315 |
|
|
2021
Q1 | $410K | Buy |
39,100
+22,500
| +136% | +$317K | ﹤0.01% | 4281 |
|
|
2020
Q4 | $281K | Sell |
16,600
-22,200
| -57% | -$333K | ﹤0.01% | 3794 |
|
|
2020
Q3 | $498K | Sell |
38,800
-35,800
| -48% | -$452K | ﹤0.01% | 2855 |
|
|
2020
Q2 | $1.05M | Buy |
74,600
+11,000
| +17% | +$139K | ﹤0.01% | 1973 |
|
|
2020
Q1 | $585K | Buy |
63,600
+53,200
| +512% | +$686K | ﹤0.01% | 1944 |
|
|
2019
Q4 | $155K | Buy |
10,400
+8,700
| +512% | +$77.5K | ﹤0.01% | 3342 |
|
|
2019
Q3 | $12K | Buy |
+1,700
| New | +$17.2K | ﹤0.01% | 4550 |
|
Other funds holding PRVB
Group One Trading's PRVB Position: Q2 2023 in Review
Group One Trading sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 24,190 shares — an estimated $583K sold.
Group One Trading first reported a position in PRVB in Q3 2019 and held it in 13 quarters. The position peaked at $1.99M in Q4 2022. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.
- Group One Trading reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Group One Trading sold 24,190 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $583K.
- Group One Trading first reported a position in Provention Bio, Inc. Common Stock in Q3 2019 and held it in 13 quarters.
- Group One Trading's Provention Bio, Inc. Common Stock position peaked at $1.99M in Q4 2022.
- 1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.
Based on Group One Trading's 13F filing for Q2 2023, filed 9 Aug 2023.